These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1334 related articles for article (PubMed ID: 32303615)

  • 1. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
    Huang D; Ke L; Cui H; Li S
    BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
    Chen Z; Chen Y; Peng L; Wang X; Tang N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
    Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
    Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV induced hepatocellular carcinoma and related potential immunotherapy.
    Jia L; Gao Y; He Y; Hooper JD; Yang P
    Pharmacol Res; 2020 Sep; 159():104992. PubMed ID: 32505833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
    Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
    Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.
    Otano I; Escors D; Schurich A; Singh H; Robertson F; Davidson BR; Fusai G; Vargas FA; Tan ZMD; Aw JYJ; Hansi N; Kennedy PTF; Xue SA; Stauss HJ; Bertoletti A; Pavesi A; Maini MK
    Mol Ther; 2018 Nov; 26(11):2553-2566. PubMed ID: 30217730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.